Scott Giberson
About Scott Giberson
Scott Giberson, RPh, MPH, D.Sc., Rear Admiral (retired), is an independent Class I director of SAB Biotherapeutics (SABS), serving since July 2022; he is 56 years old. He is President of AMI Expeditionary Healthcare (since March 2021) and previously served 27 years in U.S. public health leadership roles, including Acting Deputy Surgeon General (2013–2014), with extensive experience in global health, crisis response, and pharmacy leadership. He holds a pharmacy degree and license (Temple University), an MPH (U. Massachusetts/Amherst), a graduate certificate in Health Emergencies in Large Populations (ICRC), and three honorary doctorates; he is also a Fellow of Wharton’s Executive Leadership Program. The Board deems him independent under Nasdaq rules .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| U.S. Public Health Service / HHS | Acting Deputy Surgeon General of the United States | 2013–2014 | Principal liaison with health leadership across U.S. departments; led high-profile public health initiatives |
| U.S. Public Health Service | Chief Pharmacist (USPHS) | 2010–2014 | National pharmacy leadership; workforce and policy oversight |
| HHS (various) | Assistant U.S. Surgeon General; Senior Advisor to the Office of Surgeon General; Director of Commissioned Corps HQ | 2010–2021 | Senior leadership roles across operations and strategy |
| Indian Health Service | Director, National HIV/AIDS Program | (year not specified beyond tenure range) | Program leadership for HIV/AIDS within IHS |
| PACOM Center of Excellence in Disaster Mgmt & Humanitarian Assistance | Senior Public Health Advisor | 2003–2006 | Disaster and humanitarian response advisory |
| USPHS Ebola Response (West Africa) | Overall Commander | (within 2010–2021 tenure) | Led Ebola response; awarded Presidential Unit Citation |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| AMI Expeditionary Healthcare (private) | President | Mar 2021–present | Global healthcare solutions; clients include U.S./foreign governments, WHO, UN, Gates Foundation |
Board Governance
| Attribute | Detail |
|---|---|
| Board Class/Term | Class I director; Class I terms expire immediately following the annual meeting for the calendar year ended Dec 31, 2025 (re-nomination/election cycle thereafter) |
| Independence | Independent director under Nasdaq rules (Board determination) |
| Committees | Nominating & Corporate Governance Committee (member); Chair is David Link; 5 meetings in 2024. Not a member of Audit or Compensation committees |
| Attendance | In 2024, each director attended at least 75% of aggregate Board and applicable committee meetings |
| Executive Sessions | 7 meetings of independent directors in 2024 |
Fixed Compensation
| Metric | 2023 | 2024 |
|---|---|---|
| Fees Earned or Paid in Cash ($) | 25,000 | 30,250 |
Director cash retainer structure (effective 2024/2025):
- Base annual cash retainer: $30,000 (independent directors)
- Committee Chair retainers: Audit $8,000; Compensation $7,000; Nominating & Governance $6,000
- Committee Member retainers: Audit $6,000; Compensation $5,000; Nominating & Governance $4,000
Performance Compensation
| Component | 2023 | 2024 | Vesting / Structure |
|---|---|---|---|
| Option Awards (Grant-Date Fair Value, $) | — (no option award disclosed for Giberson in 2023) | 45,822 | Standard director program: Initial option for 35,000 shares vests in 3 equal annual installments; Annual option for 20,000 shares vests in 2 equal annual installments, both beginning on first anniversary of grant |
- Performance metrics: No director-specific performance metrics (e.g., revenue/EBITDA/TSR) are tied to director equity awards; options are service-vested per policy .
- Equity plan terms and CIC: The omnibus plan defines “Change in Control” and permits the committee/board to impose forfeiture or acceleration terms upon termination/CIC per award agreements; directors’ awards are granted at the Board’s discretion (no director-specific CIC acceleration terms disclosed) .
Other Directorships & Interlocks
| Company | Public/Private | Role | Notes |
|---|---|---|---|
| — | — | — | No other public company directorships disclosed for Mr. Giberson in the proxy |
- Interlocks/Conflicts: No related-party transactions involving Mr. Giberson are disclosed; the Company’s audit committee must pre-approve and review related party transactions per policy .
Expertise & Qualifications
- Global health and crisis leadership: Acting Deputy Surgeon General; led USPHS Ebola Response; extensive HHS senior service; Presidential Unit Citation recipient .
- Operational leadership: President of AMI Expeditionary Healthcare with global government and NGO clients .
- Credentials: Pharmacy degree and license; MPH; graduate certificate (ICRC); three honorary doctorates; Wharton Executive Leadership Program Fellow .
Equity Ownership
| As-Of Date | Total Beneficial Ownership (shares) | Composition | % of Outstanding |
|---|---|---|---|
| May 13, 2024 | 1,672 | Includes shares and options exercisable within 60 days per SEC rules (not itemized) | <1% (“*” denotes less than 1%) |
| Mar 21, 2025 | 2,362 | Includes shares and options exercisable within 60 days per SEC rules (not itemized) | <1% (“*” denotes less than 1%) |
| Aug 1, 2025 | 12,500 | Consists of 12,500 shares underlying stock options exercisable within 60 days | <1% (“*” denotes less than 1%) |
Additional alignment policies:
- Hedging is prohibited for directors, officers, and employees under the Company’s Insider Trading Policy .
Governance Assessment
- Independence and attendance: Independent under Nasdaq; met or exceeded 75% attendance threshold in 2024—supportive of engagement standards .
- Committee impact: Serves on Nominating & Governance; committee met five times in 2024—indicates active governance process; not on Audit or Compensation (limits direct influence over financial reporting or pay design) .
- Pay structure and alignment: Director cash retainers increased from $25,000 (2023) to $30,000 base plus committee fees (2024/2025); equity granted as time-vested stock options with clear vesting schedules—typical alignment mechanism, but not performance-based .
- Ownership “skin in the game”: Beneficial ownership remains <1%; as of Aug 1, 2025 consists of 12,500 options exercisable within 60 days; no pledging disclosures and hedging is prohibited—alignment exists but magnitudes are modest for an independent director of a micro-cap .
- Conflicts/related parties: No Mr. Giberson-related transactions disclosed; audit committee oversees related-party reviews per policy—no specific red flags identified for this director .
RED FLAGS
- None specific to Mr. Giberson identified in Company disclosures: no attendance shortfalls, no related-party transactions, no hedging/pledging issues disclosed .